114
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Prevalence and Pattern of Resistance in NS5A/NS5B in Hepatitis C Chronic Patients Genotype 3 Examined at a Public Health Laboratory in the State of São Paulo, Brazil

ORCID Icon, , ORCID Icon, , ORCID Icon, ORCID Icon, , , & ORCID Icon show all
Pages 723-730 | Published online: 24 Feb 2021

References

  • Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019;393(10178):1319–1329. doi:10.1016/S0140-6736(18)32277-330704789
  • European Association for the Study of the Liver (EASL). Recommendations on treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461‐511
  • World Health Organization (WHO). Global hepatitis report, 2017. Geneva; 2017. Available from: https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf. Accessed 815, 2019.
  • Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1suppl):S45–S57. doi:10.1016/j.jhep.2014.07.02725086286
  • Sagnelli E, Starace M, Minichini C, et al. Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure. Infection. 2018;46(6):761–783. doi:10.1007/s15010-018-1188-330084057
  • Hezode C, Reau N, Svarovskaia ES, et al. Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the Phase III studies. J Hepatol. 2018;68(5):895–903. doi:10.1016/j.jhep.2017.11.03229221887
  • Kim CW, Chang KM. Hepatitis C virus: virology and life cycle. Clin Mol Hepatol. 2013;19(1):17‐25. doi:10.3350/cmh.2013.19.1.17
  • Scheel TKD, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med. 2013;19(7):837–849. doi:10.1038/nm.324823836234
  • Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151(1):70‐86. doi:10.1053/j.gastro.2016.04.003
  • Hussain T. Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review. Hepat Med. 2016;8:61–68. doi:10.2147/HMER.S7242927274322
  • Vermehren J, Sarrazin C. The role of resistance in HCV treatment. Best Pract Res Clin Gastroenterol. 2012;26(4):487–503. doi:10.1016/j.bpg.2012.09.01123199507
  • Malta FM, Medeiros-Filho JE, Azevedo RS, et al. Sequencing of E2 and NS5A regions of HCV genotype 3a in Brazilian patients with chronic hepatitis. Mem Inst Oswaldo Cruz. 2010;105(1):92–98. doi:10.1590/S0074-0276201000010001420209336
  • Sandres-Sauné K, Deny P, Pasquier C, Thibaut V, Duverlie G, Izopet J. Determining hepatitis C genotype by analyzing the sequence of the NS5b region. J Virol Methods. 2003;109(2):187–193. doi:10.1016/S0166-0934(03)00070-312711062
  • Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA. 1977;74(12):5463–5467. doi:10.1073/pnas.74.12.5463271968
  • Sharafi H, Alavian SM. Hepatitis C resistance to NS5A inhibitors: is it going to be a problem? World J Hepatol. 2018;10(9):543–548. doi:10.4254/wjh.v10.i9.54330310532
  • Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64(2):486‐504. doi:10.1016/j.jhep.2015.09.011
  • Sorbo MC, Cento V, Di Maio VC, et al. Hepatitis C virus drug resistance associated substitutions and their clinical relevance. Drug Resist Updat. 2018;37:17–39. doi:10.1016/j.drup.2018.01.00429525636
  • Bartolini B, Giombini E, Taibi C, et al. Characterization of naturally occurring NS5A and NS5B polymorphisms in patients infected with HCV genotype 3a treated with direct-acting antiviral agents. Viruses. 2017;9(8):212. doi:10.3390/v9080212
  • Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA. In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother. 2013;57(1):611‐613. doi:10.1128/AAC.01874-12
  • Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013;57(1):13–18. doi:10.1016/j.jcv.2012.12.02023384816
  • Ng TI, Krishnan P, Pilot-Matias T, et al. In vitro antiviral activity and resistance profile of the next-generation Hepatitis C Virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother. 2017;61(5):e02558–16. doi:10.1128/AAC.02558-1628193664
  • Gottwein JM, Pham LV, Mikkelsen LS, et al. Efficacy of NS5A inhibitors against Hepatitis C Virus genotypes 1–7 and escape variants. Gastroenterology. 2018;154(5):1435‐1448. doi:10.1053/j.gastro.2017.12.015
  • Kalaghatgi P, Sikorski AM, Knops E, et al. Geno2pheno [HCV] - A web-based interpretation system to support Hepatitis C treatment decisions in the era of direct-acting antiviral agents. PLoS One. 2016;11(5):e0155869. doi:10.1371/journal.pone.015586927196673
  • Chen Q, Perales C, Soria ME, et al. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Res. 2020;174:104694. doi:10.1016/j.antiviral.2019.10469431857134
  • Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme AM, Rockstroh JK. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Rev Med Virol. 2016;26(6):408–434. doi:10.1002/rmv.189527401933
  • Kjellin M, Kileng H, Akaberi D, et al. Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from multicenter study in Sweden and Norway. Scand J Gastroenterol. 2019;54(8):1042‐1050. doi:10.1080/00365521.2019.1652846
  • Krishnan P, Pilot-Matias Y, Schnell G, et al. Pooled resistance analysis in patients with Hepatitis C Virus genotype 1 to 6 infection treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 clinical trials. Antimicrob Agents Chemother. 2018;62(10):e01249–18. doi:10.1128/AAC.01249-1830061289
  • Lawitz EJ, Dvory-Sobol H, Doehle BP, et al. Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the Hepatitis C Virus NS5A protein. Antimicrob Agents Chemother. 2016;60(9):5368‐5378. doi:10.1128/AAC.00763-16
  • Costa VD, Brandão-Mello CE, Nunes EP, et al. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes. PLoS One. 2019;14(5):e0216327. doi:10.1371/journal.pone.021632731063475
  • Ministry of Health (MS). Clinical protocol and therapeutic guidelines for viral hepatitis C and coinfections. HCV genotype 1 and advanced fibrosis. Brasília – Df; 2013; Suppl 2:26. Available from: http://www.saude.gov.br/images/pdf/2014/abril/02/pcdt-hepatite-c-suplemento-2013.pdf. Accessed 727, 2020.